查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1559019

尿失禁治疗市场：全球产业分析、规模、占有率、成长、趋势，2024-2031年预测

Urinary Incontinence Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 170 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research最近发布了一份关于全球尿失禁治疗市场的综合报告。本报告对关键市场动态进行了深入分析，包括市场驱动因素、趋势、机会和挑战，并对市场结构提供了深入的见解。

主要见解

  • 尿失禁治疗市场规模（2024年）：44亿美元
  • 预估市场规模（2031年）：58亿美元
  • 全球市场成长率（2024-2031年年复合成长率）：4.1%

尿失禁治疗市场：调查范围

尿失禁治疗包括多种目的是控制和缓解尿失禁症状的治疗方法，尿失禁影响世界上很大一部分人口。这些治疗包括药物治疗、手术介入和非药物管理策略。该市场以医院、诊所、泌尿中心和家庭护理机构为目标，提供多种治疗选择，包括抗胆碱能药物、β-3 肾上腺素促效剂、手术设备和骨盆底肌肉训练。

市场促进要因：

全球尿失禁治疗市场由几个关键因素推动，包括老龄化人口中尿失禁盛行率的上升以及对可用治疗方案的认识不断提高。治疗技术的进步，例如微创手术技术和新型药物製剂，提高治疗效果和患者满意度。此外，日益采用生活方式改变和行为疗法以及医疗保健成本的上升也推动了市场扩张。

市场抑制要因：

虽然尿失禁治疗市场有望实现积极成长，但它面临着治疗成本高、保险覆盖范围有限以及患者对各种治疗反应不同等挑战。先进外科手术和长期药物治疗的高成本可能成为市场进入的障碍，特别是在医疗保健预算有限的新兴国家。此外，新疗法的监管障碍和严格的审批流程对市场进入造成了障碍，影响了创新和市场成长的步伐。

市场机会：

由于持续的研究和开发、人口变化以及治疗模式的新兴市场发展，尿失禁治疗市场带来了巨大的商机。药物配方的创新，例如缓释配方和联合治疗，可以提高患者的依从性和治疗结果。数位医疗技术的整合，包括行动医疗应用和远距医疗，将改善患者获得治疗和后续护理的机会。此外，策略合作伙伴关係、临床试验投资以及开发具有成本效益的治疗解决方案对于利用新机会和维持市场成长非常重要。

本报告涵盖的主要问题

  • 推动全球尿失禁治疗市场成长的关键因素是什么？
  • 哪些治疗类型和方式引领各种医疗机构采用尿失禁治疗？
  • 技术进步如何改变尿失禁治疗市场的竞争格局？
  • 谁是尿失禁治疗市场的主要参与者？
  • 全球尿失禁治疗市场的新趋势与未来前景如何？

目次

第1章 执行摘要

第2章 市场概要

  • 市场范围与定义
  • 市场动态
    • 促进要因
    • 抑制要因
    • 机会
    • 课题
    • 主要动向
  • 宏观经济因素
    • 世界产业展望
    • 全球 GDP 成长前景
    • 全球医疗支出展望
  • 新冠肺炎（COVID-19）影响分析
  • 预测因子 - 相关性和影响

第3章 附加价值见解

  • 药物类型采用分析
  • 监理状况
  • 价值链分析
    • 最终用户/市场列表
      • 零售
      • 听力学
      • 电子商务
    • 最终用户（行业）列表
  • 主要交易和合併
  • PESTLE分析
  • 波特五力分析

第4章 尿失禁治疗市场展望：実绩（2019～2023年）と予测（2024～2031年）

  • 主要亮点
    • 市场规模（十亿美元）和年成长率
    • 绝对数量的机会
  • 市场规模分析与预测（十亿美元）
    • 过去的市场规模（十亿美元）分析，2019-2023年
    • 当前市场规模（十亿美元）分析与预测，2024-2031年
  • 尿失禁治疗市场前景：类型
    • 简介/主要调查结果
    • 2019-2023年历史市场规模（十亿美元）分析，依类型
    • 当前市场规模（十亿美元）分析与预测，2024-2031年，依类型
      • 急迫性尿失禁
      • 溢流性失禁
      • 压力性尿失禁
      • 机能性失禁
      • 其他
  • 市场吸引力分析：类型
  • 尿失禁治疗市场前景：药物类别
    • 简介/主要调查结果
    • 2019-2023年历史市场规模（十亿美元）分析，依药物类别
    • 2024-2031年当前市场规模（十亿美元）的分析和预测，依药物类别
      • 抗胆碱能药物
      • β3 肾上腺素受体促效剂
      • α受体阻断剂
      • 雌激素
      • 去氨加压素
      • 三环抗忧郁药
      • 其他
  • 市场吸引力分析：药品类别
  • 尿失禁治疗市场前景：最终用户
    • 简介/主要调查结果
    • 2019-2023年历史市场规模（十亿美元）分析，依最终用户
    • 2024-2031目前市场规模（十亿美元）的分析与预测，依最终用户
      • 病院
      • 零售药局
      • 网路药局
  • 市场吸引力分析：最终用户

第5章 尿失禁治疗市场展望：地域

  • 2019-2023年过去市场规模（十亿美元）分析，依地区
  • 2024-2031年当前市场规模（十亿美元）分析和预测，依地区
    • 北美
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东、非洲
  • 市场吸引力分析：地区

第6章 北美尿失禁治疗市场展望：实绩（2019-2023）与预测（2024-2031）

第7章 欧洲尿失禁治疗市场展望：实绩（2019-2023年）与预测（2024-2031年）

第8章 东亚尿失禁治疗市场展望：实绩（2019-2023年）与预测（2024-2031年）

第9章 南亚和大洋洲尿失禁治疗市场展望：实绩（2019-2023年）和预测（2024-2031年）

第10章 拉丁美洲尿失禁治疗市场展望：实绩（2019-2023年）与预测（2024-2031年）

第11章 中东和非洲尿失禁治疗市场展望：实绩（2019-2023年）和预测（2024-2031年）

第12章 竞争情势

  • 2023年市场占有率分析
  • 市场构造
    • 依市场划分的竞争强度图
    • 竞争仪表板
  • 公司简介（详细资料 - 概述、财务状况、策略、近期发展）
    • Pfizer Inc
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Johnson &Johnson
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Bayer AG
    • Ferring Pharmaceuticals

第13章 附录

  • 调查方法
  • 调查假设
  • 首字母缩写词和缩写词
简介目录
Product Code: PMRREP34774

Persistence Market Research has recently released a comprehensive report on the worldwide market for urinary incontinence therapeutics. The report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.

Key Insights:

  • Urinary Incontinence Therapeutics Market Size (2024E): US$4.4 Bn
  • Projected Market Value (2031F): US$5.8 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.1%

Urinary Incontinence Therapeutics Market - Report Scope:

Urinary incontinence therapeutics encompass a range of treatments designed to manage and alleviate symptoms of urinary incontinence, a condition affecting a substantial portion of the global population. These therapeutics include pharmacological treatments, surgical interventions, and non-pharmacological management strategies. The market caters to hospitals, clinics, urology centers, and homecare settings, offering a variety of therapeutic options, including anticholinergics, beta-3 adrenergic agonists, surgical devices, and pelvic floor muscle training.

Market Growth Drivers:

The global urinary incontinence therapeutics market is driven by several key factors, including the rising prevalence of urinary incontinence among the aging population and increasing awareness about available treatment options. Advances in therapeutic technologies, such as minimally invasive surgical techniques and novel pharmacological agents, are enhancing treatment efficacy and patient satisfaction. Additionally, the growing adoption of lifestyle modifications and behavioral therapies, along with increasing healthcare expenditures, is fueling market expansion.

Market Restraints:

Despite positive growth prospects, the urinary incontinence therapeutics market faces challenges related to high treatment costs, limited insurance coverage, and variability in patient response to different therapies. The high cost of advanced surgical procedures and long-term pharmacological treatments can be a barrier to market accessibility, particularly in emerging economies with constrained healthcare budgets. Moreover, regulatory hurdles and stringent approval processes for new therapeutics contribute to market entry barriers, affecting the pace of innovation and market growth.

Market Opportunities:

The urinary incontinence therapeutics market presents significant opportunities driven by ongoing research and development, demographic shifts, and evolving treatment paradigms. Innovations in drug formulations, such as extended-release and combination therapies, offer improved patient compliance and therapeutic outcomes. The integration of digital health technologies, including mobile health applications and telemedicine, enhances patient access to treatment and follow-up care. Furthermore, strategic partnerships, investment in clinical trials, and the development of cost-effective treatment solutions are crucial to capitalizing on emerging opportunities and sustaining market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the urinary incontinence therapeutics market globally?
  • Which therapeutic types and treatment modalities are leading the adoption of urinary incontinence therapies across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the urinary incontinence therapeutics market?
  • Who are the key players contributing to the urinary incontinence therapeutics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global urinary incontinence therapeutics market?

Competitive Intelligence and Business Strategy:

Leading players in the global urinary incontinence therapeutics market, including Pfizer Inc., Astellas Pharma Inc., Allergan plc, and Medtronic plc, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced therapeutic solutions, including novel drug formulations and innovative surgical devices, catering to diverse patient needs and clinical requirements. Partnerships with healthcare providers, regulatory agencies, and research institutions facilitate market access and promote technology adoption. Emphasis on clinical research, patient education, and personalized treatment approaches drives market growth and enhances patient outcomes in the evolving urinary incontinence therapeutics landscape.

Key Companies Profiled:

  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Allergan plc
  • Medtronic plc
  • Boston Scientific Corporation
  • Coloplast A/S
  • Urovant Sciences Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Endo International plc
  • Kaken Pharmaceutical Co., Ltd.

Urinary Incontinence Therapeutics Industry Segmentation

By Type

  • Urge Incontinence
  • Overflow Incontinence
  • Stress Incontinence
  • Functional Incontinence

By Drug Class

  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants

By End User

  • Hospitals
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Urinary Incontinence Therapeutics Market Snapshot, 2024-2031
  • 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Drug Type Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
    • 3.3.1. List of End-user/Marketplaces
      • 3.3.1.1. Retail
      • 3.3.1.2. Audiology
      • 3.3.1.3. E-Commerce
    • 3.3.2. List of End User (Industry)
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
  • 4.3. Urinary Incontinence Therapeutics Market Outlook: Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019-2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
      • 4.3.3.1. Urge Incontinence
      • 4.3.3.2. Overflow Incontinence
      • 4.3.3.3. Stress Incontinence
      • 4.3.3.4. Functional Incontinence
      • 4.3.3.5. Other
  • 4.4. Market Attractiveness Analysis: Type
  • 4.5. Urinary Incontinence Therapeutics Market Outlook: Drug Class
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
      • 4.5.3.1. Anticholinergics
      • 4.5.3.2. Beta-3 Adrenoceptor Agonists
      • 4.5.3.3. Alpha Blockers
      • 4.5.3.4. Estrogen
      • 4.5.3.5. Desmopressin
      • 4.5.3.6. Tricyclic Antidepressants
      • 4.5.3.7. Other
  • 4.6. Market Attractiveness Analysis: Drug Class
  • 4.7. Urinary Incontinence Therapeutics Market Outlook: End-user
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By End-user, 2019-2023
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
      • 4.7.3.1. Hospitals
      • 4.7.3.2. Retail Pharmacy
      • 4.7.3.3. Online Pharmacy
  • 4.8. Market Attractiveness Analysis: End-user

5. Urinary Incontinence Therapeutics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 6.3.1. By Country
    • 6.3.2. By Type
    • 6.3.3. By Drug Class
    • 6.3.4. By End-user
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 6.4.1. U.S.
    • 6.4.2. Canada
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 6.5.1. Urge Incontinence
    • 6.5.2. Overflow Incontinence
    • 6.5.3. Stress Incontinence
    • 6.5.4. Functional Incontinence
    • 6.5.5. Other
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 6.6.1. Anticholinergics
    • 6.6.2. Beta-3 Adrenoceptor Agonists
    • 6.6.3. Alpha Blockers
    • 6.6.4. Estrogen
    • 6.6.5. Desmopressin
    • 6.6.6. Tricyclic Antidepressants
    • 6.6.7. Other
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 6.7.1. Hospitals
    • 6.7.2. Retail Pharmacy
    • 6.7.3. Online Pharmacy
  • 6.8. Market Attractiveness Analysis

7. Europe Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 7.3.1. By Country
    • 7.3.2. By Type
    • 7.3.3. By Drug Class
    • 7.3.4. By End-user
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. U.K.
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Russia
    • 7.4.7. Turkey
    • 7.4.8. Rest of Europe
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 7.5.1. Urge Incontinence
    • 7.5.2. Overflow Incontinence
    • 7.5.3. Stress Incontinence
    • 7.5.4. Functional Incontinence
    • 7.5.5. Other
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 7.6.1. Anticholinergics
    • 7.6.2. Beta-3 Adrenoceptor Agonists
    • 7.6.3. Alpha Blockers
    • 7.6.4. Estrogen
    • 7.6.5. Desmopressin
    • 7.6.6. Tricyclic Antidepressants
    • 7.6.7. Other
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 7.7.1. Hospitals
    • 7.7.2. Retail Pharmacy
    • 7.7.3. Online Pharmacy
  • 7.8. Market Attractiveness Analysis

8. East Asia Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 8.3.1. By Country
    • 8.3.2. By Type
    • 8.3.3. By Drug Class
    • 8.3.4. By End-user
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. South Korea
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 8.5.1. Urge Incontinence
    • 8.5.2. Overflow Incontinence
    • 8.5.3. Stress Incontinence
    • 8.5.4. Functional Incontinence
    • 8.5.5. Other
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 8.6.1. Anticholinergics
    • 8.6.2. Beta-3 Adrenoceptor Agonists
    • 8.6.3. Alpha Blockers
    • 8.6.4. Estrogen
    • 8.6.5. Desmopressin
    • 8.6.6. Tricyclic Antidepressants
    • 8.6.7. Other
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 8.7.1. Hospitals
    • 8.7.2. Retail Pharmacy
    • 8.7.3. Online Pharmacy
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 9.3.1. By Country
    • 9.3.2. By Type
    • 9.3.3. By Drug Class
    • 9.3.4. By End-user
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 9.4.1. India
    • 9.4.2. Southeast Asia
    • 9.4.3. ANZ
    • 9.4.4. Rest of South Asia & Oceania
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 9.5.1. Urge Incontinence
    • 9.5.2. Overflow Incontinence
    • 9.5.3. Stress Incontinence
    • 9.5.4. Functional Incontinence
    • 9.5.5. Other
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 9.6.1. Anticholinergics
    • 9.6.2. Beta-3 Adrenoceptor Agonists
    • 9.6.3. Alpha Blockers
    • 9.6.4. Estrogen
    • 9.6.5. Desmopressin
    • 9.6.6. Tricyclic Antidepressants
    • 9.6.7. Other
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 9.7.1. Hospitals
    • 9.7.2. Retail Pharmacy
    • 9.7.3. Online Pharmacy
  • 9.8. Market Attractiveness Analysis

10. Latin America Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 10.3.1. By Country
    • 10.3.2. By Type
    • 10.3.3. By Drug Class
    • 10.3.4. By End-user
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 10.4.1. Brazil
    • 10.4.2. Mexico
    • 10.4.3. Rest of Latin America
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 10.5.1. Urge Incontinence
    • 10.5.2. Overflow Incontinence
    • 10.5.3. Stress Incontinence
    • 10.5.4. Functional Incontinence
    • 10.5.5. Other
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 10.6.1. Anticholinergics
    • 10.6.2. Beta-3 Adrenoceptor Agonists
    • 10.6.3. Alpha Blockers
    • 10.6.4. Estrogen
    • 10.6.5. Desmopressin
    • 10.6.6. Tricyclic Antidepressants
    • 10.6.7. Other
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 10.7.1. Hospitals
    • 10.7.2. Retail Pharmacy
    • 10.7.3. Online Pharmacy
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 11.1. Key Highlights
  • 11.2. Pricing Analysis
  • 11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 11.3.1. By Country
    • 11.3.2. By Type
    • 11.3.3. By Drug Class
    • 11.3.4. By End-user
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 11.4.1. GCC Countries
    • 11.4.2. Egypt
    • 11.4.3. South Africa
    • 11.4.4. Northern Africa
    • 11.4.5. Rest of Middle East & Africa
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 11.5.1. Urge Incontinence
    • 11.5.2. Overflow Incontinence
    • 11.5.3. Stress Incontinence
    • 11.5.4. Functional Incontinence
    • 11.5.5. Other
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 11.6.1. Anticholinergics
    • 11.6.2. Beta-3 Adrenoceptor Agonists
    • 11.6.3. Alpha Blockers
    • 11.6.4. Estrogen
    • 11.6.5. Desmopressin
    • 11.6.6. Tricyclic Antidepressants
    • 11.6.7. Other
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 11.7.1. Hospitals
    • 11.7.2. Retail Pharmacy
    • 11.7.3. Online Pharmacy
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Pfizer Inc
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Type
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. AbbVie Inc.
    • 12.3.3. Astellas Pharma Inc.
    • 12.3.4. Johnson & Johnson
    • 12.3.5. Viatris Inc.
    • 12.3.6. Teva Pharmaceutical Industries Ltd.
    • 12.3.7. Sanofi S.A.
    • 12.3.8. GlaxoSmithKline plc
    • 12.3.9. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 12.3.10. Bayer AG
    • 12.3.11. Ferring Pharmaceuticals

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations